. 2020 Sep 12;4(12):1731–1743. doi: 10.1002/hep4.1600

Table 1.

Several COVID‐19 antibody tests that are used in diagnostics and epidemiology

	Technology Used	Sensitivity	Specificity	Strengths	Weaknesses
IgG	CGIA⁽ ⁹⁶ ⁾	29.7%‐88.2%	98.8%‐99.5%	‐ High specificity ‐ LFA available kits low cost	‐ Low early sensitivity ‐ Scarce data after 35 days ‐ Neutralizing effect N/A
	CLIA⁽ ¹²⁴ ⁾
	ELISA⁽ ¹²⁵ ⁾
	LFA⁽ ¹²⁶ ⁾
IgM	CGIA⁽ ⁹⁶ ⁾	23.2%‐75.4%	97.3%‐99.6%	‐ High specificity ‐ LFA available kits low cost	‐ Low early sensitivity ‐ Scarce data after 35 days ‐ Neutralizing effect N/A
	CLIA⁽ ¹²⁴ ⁾
	ELISA⁽ ¹²⁵ ⁾
	LFA⁽ ¹²⁶ ⁾
IgG/IgM	CGIA⁽ ⁴⁴ ⁾	30.1%‐91.4%	94.1%‐99.4%	‐ High specificity ‐ LFA available kits low cost	‐ Low early sensitivity ‐ Scarce data after 35 days ‐ Neutralizing effect N/A
	CLIA⁽ ¹²⁷ ⁾
	ELISA⁽ ¹²⁸ ⁾
	LFA⁽ ⁹⁶ ⁾

Abbreviations: CGIA, colloidal gold immunoassay; CLIA, chemiluminescence immunoassay; LFA, lateral flow assay; N/A not applicable.